Drug intelligence / Profile preview

FenAb024

Development stage: Preclinical
Lead developer: Panosome
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

FenAb024 (also known as PNSM024) is a monoclonal antibody developed by Panosome and licensed to Hepione Therapeutics for the treatment of carfentanil poisoning and as a biodefense countermeasure. It is designed to neutralize carfentanil, a highly potent synthetic opioid, by binding to the molecule in the bloodstream and preventing it from crossing the blood-brain barrier to interact with opioid receptors. This "immunopharmacotherapy" approach aims to provide protection for military personnel, first responders, and high-risk populations exposed to carfentanil. The drug is currently in preclinical development (lead selection phase).

Other names: anti-Carfentanil

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on FenAb024.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FenAb024.

Explore the full profile